Hansa Biopharma Balance Sheet Health
Financial Health criteria checks 2/6
Hansa Biopharma has a total shareholder equity of SEK-62.2M and total debt of SEK906.7M, which brings its debt-to-equity ratio to -1457.5%. Its total assets and total liabilities are SEK1.2B and SEK1.2B respectively.
Key information
-1,457.5%
Debt to equity ratio
kr906.68m
Debt
| Interest coverage ratio | n/a |
| Cash | kr908.18m |
| Equity | -kr62.21m |
| Total liabilities | kr1.23b |
| Total assets | kr1.17b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: HNSAS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: HNSAS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: HNSAS has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: HNSAS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HNSAS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: HNSAS has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 22.8% each year.